Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift

Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. O.E. Irhuma, M. Vally
Formato:	article
Lenguaje:	EN
Publicado:	AOSIS 2016
Materias:	ace-inhibitors angiotensin receptor blockers arbs enalapril heart failure hfref management neprilysin inhibitors sacubitril valsartan Medicine R
Acceso en línea:	https://doaj.org/article/801839061dbb4212a01f2e4dfd12d184
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:801839061dbb4212a01f2e4dfd12d184
record_format	dspace
spelling	oai:doaj.org-article:801839061dbb4212a01f2e4dfd12d1842021-11-24T07:44:19ZUse of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift2078-61902078-620410.4102/safp.v58i5.4524https://doaj.org/article/801839061dbb4212a01f2e4dfd12d1842016-11-01T00:00:00Zhttps://safpj.co.za/index.php/safpj/article/view/4524https://doaj.org/toc/2078-6190https://doaj.org/toc/2078-6204Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a growing public health problem. Pathophysiologically, heart failure clinically presents in two common forms: heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. The cornerstone of heart failure management includes the use of angiotensin-converting enzyme inhibitors. A recently developed pharmacotherapy that inhibits both the angiotensin receptor and the enzyme neprilysin has shown promise in the management of heart failure with reduced ejection fraction. This article will highlight the impact of this new therapy and its potential use in heart failure with reduced ejection fraction.M. O.E. IrhumaM. VallyAOSISarticleace-inhibitorsangiotensin receptor blockersarbsenalaprilheart failurehfref managementneprilysin inhibitorssacubitrilvalsartanMedicineRENSouth African Family Practice, Vol 58, Iss 5, Pp 60-63 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	ace-inhibitors angiotensin receptor blockers arbs enalapril heart failure hfref management neprilysin inhibitors sacubitril valsartan Medicine R
spellingShingle	ace-inhibitors angiotensin receptor blockers arbs enalapril heart failure hfref management neprilysin inhibitors sacubitril valsartan Medicine R M. O.E. Irhuma M. Vally Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
description	Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a growing public health problem. Pathophysiologically, heart failure clinically presents in two common forms: heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. The cornerstone of heart failure management includes the use of angiotensin-converting enzyme inhibitors. A recently developed pharmacotherapy that inhibits both the angiotensin receptor and the enzyme neprilysin has shown promise in the management of heart failure with reduced ejection fraction. This article will highlight the impact of this new therapy and its potential use in heart failure with reduced ejection fraction.
format	article
author	M. O.E. Irhuma M. Vally
author_facet	M. O.E. Irhuma M. Vally
author_sort	M. O.E. Irhuma
title	Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
title_short	Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
title_full	Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
title_fullStr	Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
title_full_unstemmed	Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
title_sort	use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
publisher	AOSIS
publishDate	2016
url	https://doaj.org/article/801839061dbb4212a01f2e4dfd12d184
work_keys_str_mv	AT moeirhuma useofangiotensinreceptorneprilysininhibitorsinheartfailureaparadigmshift AT mvally useofangiotensinreceptorneprilysininhibitorsinheartfailureaparadigmshift
_version_	1718415868255272960

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift

Ejemplares similares